South Africa's Tax Court Delivers Its First GAAR Ruling on Dividend‑stripping: Seven Appeals Dismissed

On 3 July 2026, South Africa’s Tax Court delivers its first reported judgment squarely addressing the general anti‑avoidance rule (GAAR) in the context of dividend‑stripping. In Company AF (Pty) Ltd and Others v Commissioner for the South African Revenue Service, the Cape Town Tax Court (Francis J) dismissed seven consolidated appeals, upholding additional assessments raised by SARS under sections 80A–80L of the Income Tax Act. The decision marks the first time a South African court has applied the Constitutional Court’s Absa counterfactual framework to a pre‑disposal dividend structure, treating what the appellants characterised as exempt intercompany dividends as taxable share‑sale proceeds for capital gains tax purposes.

For M&A tax advisers, in‑house counsel and transaction planners, this judgment reshapes the risk calculus around every pre‑sale restructuring that relies on the section 10(1)(k)(i) dividend exemption.

What Happened: Tax Court Hands Down First Reported GAAR Ruling on Dividend‑Stripping

The Tax Court sitting in Cape Town heard seven linked appeals arising from a series of transactions in which the appellants, a group of related entities, disposed of shares in a target company. Prior to the disposal, the structure was reorganised so that dividends were declared and subscription proceeds routed through interposed entities. The economic effect was to convert what would otherwise have been taxable sale proceeds into distributions qualifying for the intercompany dividend exemption under section 10(1)(k)(i) of the Income Tax Act.

SARS invoked the GAAR, disregarded the dividend and subscription steps, and raised additional assessments treating the full amounts received as proceeds on the disposal of shares, subject to capital gains tax (CGT) accordingly. All seven appeals were dismissed, with costs.

The role of the Tax Court as a specialist tribunal is to rehear disputes afresh on both fact and law. In this instance, the court conducted a detailed factual inquiry into the commercial substance of each step and then applied the legal framework established by the Constitutional Court in Absa Bank Ltd and Another v Commissioner for SARS (CCT72/24). The result is the most significant post‑Absa decision for corporate tax planning in South Africa and signals an emboldened enforcement posture from SARS in M&A transactions.

The Legal Test Applied: Absa Counterfactual and the GAAR Framework

South Africa’s GAAR, codified in sections 80A–80L of the Income Tax Act, empowers SARS to disregard an “impermissible avoidance arrangement.” The provision requires SARS to demonstrate that an arrangement results in a tax benefit, that it was entered into or carried out for the sole or main purpose of obtaining that benefit, and that the means or manner of the arrangement is commercially abnormal, or that it constitutes a misuse or abuse of the provisions of the Act.

In its landmark May 2026 decision in Absa Bank Ltd and Another v Commissioner for SARS, the Constitutional Court established a counterfactual methodology for testing GAAR. The court held that the enquiry must compare the impugned arrangement against a hypothetical “normal” commercial transaction, the counterfactual, to determine whether the steps in question were commercially abnormal or exploited statutory provisions in ways Parliament did not intend.

Absa Counterfactual Test, Stepwise Checklist

Based on the Constitutional Court’s reasoning, the Absa counterfactual test proceeds through a structured sequence:

• Identify the arrangement. Delineate every step and party involved in the series of transactions that produced the tax benefit.
• Construct the counterfactual. Ask what transaction the parties would have entered into in normal commercial circumstances, absent the tax‑driven structuring.
• Isolate the features absent from the counterfactual. Determine which steps or characteristics exist solely because of the tax benefit and would not feature in the counterfactual transaction.
• Assess commercial abnormality. Test whether the means or manner of the arrangement, including timing, circularity of funds, and lack of arm’s‑length rationale, is commercially abnormal when compared to the counterfactual.
• Test for misuse or abuse. Determine whether the arrangement exploits a statutory provision in a manner inconsistent with the purpose for which it was enacted.

How Absa Binds Lower Courts

As a Constitutional Court judgment, Absa binds every lower court in South Africa, including the Tax Court, the High Courts and the Supreme Court of Appeal. The Company AF decision is significant precisely because it represents the first reported instance of the Tax Court applying the Absa counterfactual framework. Industry observers expect subsequent Tax Court and High Court judgments to follow this template closely, giving the Absa methodology a practical operability it lacked before 3 July 2026.

How South Africa’s Tax Court Applied Absa to a Dividend‑Stripping Fact Pattern

The factual matrix in Company AF v SARS involved a corporate group preparing to sell its interest in a target company to a third‑party buyer. Before the disposal, the appellants undertook a series of restructuring steps: dividends were declared from the target to interposed entities, and subscription proceeds were circulated through the group in a manner that effectively stripped value from the shares ahead of the sale. The appellants then sold the shares, now reduced in value, and claimed that the earlier dividend flows were exempt under the section 10(1)(k)(i) intercompany dividend exemption.

Key Factual Markers the Court Relied On

Francis J identified several features of the arrangement that, taken together, demonstrated commercial abnormality:

• Timing. The dividend declarations and subscription steps were compressed into a narrow window immediately preceding the disposal, with no independent commercial driver for the timing.
• Circularity of funds. The flow of cash through the group entities was largely circular, with subscription proceeds effectively funding the dividends and no net economic change occurring within the group prior to the external sale.
• Lack of arm’s‑length rationale. No evidence was adduced that the steps would have been undertaken between unrelated parties or in the absence of the tax benefit.
• Absence of contemporaneous commercial purpose. Board minutes and contemporaneous correspondence did not disclose any commercial rationale for the restructuring independent of the tax advantage.

Outcome: How SARS’s GAAR Treatment Was Sustained

Applying the Absa counterfactual, Francis J concluded that the normal commercial transaction, the counterfactual, was a straightforward sale of shares in the target company at their full value. The interposed dividend and subscription steps were features absent from the counterfactual and existed solely to convert taxable proceeds into exempt dividends. The court found that this constituted a misuse of the section 10(1)(k)(i) exemption, which Parliament enacted to facilitate genuine intercompany distributions, not to strip sale proceeds of their taxable character ahead of a disposal.

SARS’s assessments were upheld in full. The Tax Court disregarded the dividend and subscription steps under the GAAR and treated the full consideration received by the appellants as proceeds on the disposal of shares, attracting CGT. All seven appeals were dismissed with costs. This outcome has significant ramifications for deal practitioners, particularly those advising on South African legal updates in 2026 and pre‑disposal restructuring more broadly.

Practical Implications for M&A and Tax Planning

The Company AF judgment has immediate consequences for any transaction in which a pre‑sale dividend or value‑extraction step is contemplated as part of an M&A exit. The likely practical effect will be a fundamental shift in how tax advisers approach pre‑disposal restructurings in South Africa.

Checklist: Pre‑Sale Transactions to Re‑Review Now

Transaction teams should urgently re‑examine any pending or recently completed deal that includes one or more of the following features:

• Pre‑sale special dividends. Any dividend declared in close proximity to a disposal where the dividend reduces the value of the shares being sold and the proceeds are characterised as exempt under section 10(1)(k)(i).
• Circular subscription or loan‑back structures. Arrangements in which the dividend flows are funded by subscription proceeds or loans that effectively circulate cash within the group without changing the economic position of the parties.
• Absence of documented commercial rationale. Steps for which no contemporaneous evidence of an independent commercial purpose, separate from the tax benefit, can be produced.
• Compressed timing. Restructurings that occur in a narrow window immediately before the disposal, with no evidence that timing was driven by commercial rather than tax considerations.
• Related‑party transactions without arm’s‑length benchmarking. Intra‑group steps that would not have occurred between unconnected parties on the same terms.

Deal Structures That Are Higher‑Risk After Company AF

The following categories of pre‑disposal restructuring tax planning now carry materially elevated GAAR risk:

• Dividend‑stripping in its classic form. Declaring a large pre‑sale dividend to reduce the base cost of shares, followed by a disposal at a correspondingly lower price.
• Hybrid equity/dividend instruments. Structures that convert what is economically a return on sale into a distribution qualifying for dividend exemptions.
• Deferred purchase‑price mechanisms routed through dividends. Arrangements where part of the purchase price is channelled as a post‑completion dividend rather than as a direct payment to the seller.

Practitioners who need to enforce court orders in South Africa following adverse SARS assessments should note that the procedural environment for tax disputes is becoming increasingly robust.

SARS and the Courts’ Enforcement Posture, What This Decision Signals

The Company AF judgment does not exist in isolation. It follows the Constitutional Court’s Absa decision by less than two months, and it sits alongside a broader trend of assertive SARS GAAR enforcement in M&A contexts. The SARS judgments index for 2025–2026 reflects a growing number of additional assessments raised under sections 80A–80L, particularly in connection with preference share structures, management fee arrangements and now dividend‑stripping.

Early indications suggest that SARS views the Absa framework as a powerful enforcement tool and intends to deploy it systematically against structures that convert taxable income into exempt or lower‑taxed receipts. The Company AF result validates that posture and provides SARS with a Tax Court precedent it can cite in settlement negotiations and further assessments.

Likelihood of Appeal and Litigation Timeline

Given the quantum involved and the novelty of the legal issues, industry observers expect the appellants to seek leave to appeal to the full bench of the High Court or directly to the Supreme Court of Appeal. Any appeal would need to be noted within the prescribed time limits under the Tax Administration Act. However, until an appellate court reverses or limits the ruling, the Company AF judgment stands as binding authority within the Tax Court and persuasive authority more broadly. Practitioners should not delay compliance adjustments pending a possible appeal.

Practical Framework: How to Stress‑Test a Pre‑Sale Dividend Step by Step

The following framework provides a structured methodology that advisers can apply before implementing any pre‑disposal dividend or restructuring step, drawing directly on the Absa counterfactual test as applied in Company AF.

1. Identify the economic substance and counterfactual. Map the full series of transactions and ask: what would the parties have done in the absence of the tax benefit? If the answer is a straightforward share sale at full value, the dividend step is at risk.
2. Test commercial rationale independent of tax benefits. Can the dividend be justified by cash‑flow needs, solvency management, return of surplus capital, or a genuine business reason that exists irrespective of any tax saving? Document this rationale in detail.
3. Document contemporaneous commercial reasons and alternatives considered. Board minutes, memoranda, and correspondence should record why the dividend was declared, what alternatives were evaluated, and why the chosen structure was commercially optimal, not just tax‑optimal.
4. Test for circularity and related‑party mirroring. If dividend proceeds are immediately subscribed back into the group or loaned back to the declaring entity, the arrangement will raise significant red flags. The funds must demonstrably leave the circular chain.
5. Obtain external valuations and independent board minutes. Where feasible, obtain independent valuations confirming that the dividend is consistent with the company’s distributable reserves and does not artificially deflate the share price ahead of disposal.
6. Consider pre‑clearance, tax opinions and disclosure to buyers. Where the structure is complex, consider obtaining a binding private ruling from SARS or, at minimum, a formal tax opinion from independent counsel. Disclosure of GAAR risk in sale‑and‑purchase agreements is also increasingly prudent, as buyers will now factor Company AF into their due diligence on ownership transfer procedures in South Africa.

Red flags that should halt implementation: compressed timing with no commercial explanation; circular cash flows; no contemporaneous documentation; and a structure that would not be replicated between unrelated parties.

Comparative Table, Absa v Company AF v Typical Pre‑Sale Dividend

The following table summarises the key differences and practical implications across the two leading judgments and a typical legitimate pre‑sale dividend scenario:

This comparison underscores that the critical differentiator is the presence or absence of genuine, documented commercial substance independent of the tax benefit.

Takeaways and Recommended Next Steps for Counsel and Transaction Teams

South Africa’s Tax Court delivers its first post‑Absa GAAR ruling directly relevant to M&A tax planning, and the implications are substantial. Counsel and transaction teams should act promptly:

• Audit current pipelines. Review all pending or recently completed transactions that include pre‑sale dividends or value‑extraction steps for GAAR exposure.
• Apply the Absa counterfactual. For each restructuring step, construct the counterfactual and assess whether the step would exist absent the tax benefit.
• Document rigorously. Ensure contemporaneous board minutes and correspondence record independent commercial rationale for every significant step.
• Obtain independent valuations. Where dividend declarations reduce share values ahead of disposal, obtain arm’s‑length valuations to support the commercial basis.
• Seek formal tax opinions. For high‑value or complex structures, commission independent counsel opinions addressing GAAR risk under the Absa and Company AF framework.
• Engage specialist litigation counsel early. If SARS has issued or is likely to issue additional assessments, specialist tax litigation advice is essential. The Global Law Experts lawyer directory provides access to qualified litigation practitioners across South Africa.

Sources

1. SAFLII, Company AF (Pty) Ltd and Others v Commissioner for SARS (Tax Court, 3 July 2026)
2. SARS, Tax Court Judgments Index 2025–2026
3. Lexology, Tax Court Applies the GAAR to Dividend Stripping
4. Bowmans, Cape Town Tax Court Judgment on Dividend‑Stripping
5. Constitutional Court, Absa Bank Ltd and Another v Commissioner for SARS (CCT72/24)
6. University of Pretoria, The GAAR’s Landmark Moment in Absa Bank Ltd v CSARS
7. Fanews, South Africa: Cape Town Tax Court Judgment on Dividend‑Stripping